FINWIRES · TerminalLIVE
FINWIRES

Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%

-- Gan & Lee Pharmaceuticals' (SHA:603087) subsidiary, Gan & Lee Pharmaceuticals Shandong, dosed the first subject for the phase III clinical trial of GZR33 injection, according to a Shanghai bourse filing on Wednesday.

The drug is being tested as a treatment for type 2 diabetes.

The pharmaceutical company's shares rose less than 3% during the afternoon trade.

Related Articles

Japan

Gold Futures Rise 1% to $4,767.1 Early Wednesday; Silver Futures Climb 1.8% to $77.83

Japan

Gold, Silver Futures Rise Pre-Bell as Imminent Threat of US Attack on Iran Recedes After Truce Extension

Asia

Abundante Swings to Loss in Fiscal H2

Abundate (SGX:570) booked a loss of SG$320,000 in the fiscal second half ended Feb. 28, from a profit of SG$134,000 a year earlier, according to a Wednesday filing with the Singapore Exchange.Loss per share stood at SG$0.0031 compared with earnings per share of SG$0.0013 in the year-ago period.Revenue rose 6% year over year to SG$4.1 million from SG$3.9 million, backed by strong demand for local construction activities.

$SGX:570